<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Cardiol</journal-id><journal-title-group><journal-title>The American Journal of Cardiology</journal-title></journal-title-group><issn pub-type="ppub">0002-9149</issn><issn pub-type="epub">1879-1913</issn><publisher><publisher-name>Excerpta Medica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24925802</article-id><article-id pub-id-type="pmc">4061472</article-id><article-id pub-id-type="publisher-id">S0002-9149(14)00962-X</article-id><article-id pub-id-type="doi">10.1016/j.amjcard.2014.04.008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Heart Failure</subject></subj-group></article-categories><title-group><article-title>Effect of Left Ventricular Assist Device Implantation and Heart Transplantation on Habitual Physical Activity and Quality of Life<sup><xref ref-type="fn" rid="d32e963">&#x02606;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jakovljevic</surname><given-names>Djordje G.</given-names></name><degrees>PhD</degrees><email>d.jakovljevic@ncl.ac.uk</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author"><name><surname>McDiarmid</surname><given-names>Adam</given-names></name><degrees>MB</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Hallsworth</surname><given-names>Kate</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Seferovic</surname><given-names>Petar M.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Ninkovic</surname><given-names>Vladan M.</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Parry</surname><given-names>Gareth</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Schueler</surname><given-names>Stephan</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Trenell</surname><given-names>Michael I.</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>MacGowan</surname><given-names>Guy A.</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff6" ref-type="aff">f</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom</aff><aff id="aff6"><label>f</label>Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom</aff><aff id="aff2"><label>b</label>Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom</aff><aff id="aff3"><label>c</label>Cardiology Department, Clinical Centre of Serbia, Medical School, University of Belgrade, Belgrade, Serbia</aff><aff id="aff4"><label>d</label>Department of Cardiology, Specialistic Hospital Merkur, Vrnjacka Banja, Serbia</aff><aff id="aff5"><label>e</label>Departments of Cardiothoracic Surgery and Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author: Tel: (+44) 0191 222 8257; fax: (+44) 0191 222 0723. <email>d.jakovljevic@ncl.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>01</day><month>7</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><day>01</day><month>7</month><year>2014</year></pub-date><volume>114</volume><issue>1</issue><fpage>88</fpage><lpage>93</lpage><history><date date-type="received"><day>27</day><month>1</month><year>2014</year></date><date date-type="rev-recd"><day>3</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>3</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 The Authors</copyright-statement><copyright-year>2014</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).</license-p></license></permissions><abstract><p>The present study defined the short- and long-term effects of left ventricular assist device (LVAD) implantation and heart transplantation (HT) on physical activity and quality of life (QoL). Forty patients (LVAD, n&#x000a0;= 14; HT, n&#x000a0;= 12; and heart failure [HF], n&#x000a0;= 14) and 14 matched healthy subjects were assessed for physical activity, energy expenditure, and QoL. The LVAD and HT groups were assessed postoperatively at 4 to 6&#x000a0;weeks (baseline) and 3, 6, and 12&#x000a0;months. At baseline, LVAD, HT, and HF patients demonstrated low physical activity, reaching only 15%, 28%, and 51% of that of healthy subjects (1,603 &#x000b1; 302 vs 3,036 &#x000b1; 439 vs 5,490 &#x000b1; 1,058 vs 10,756 &#x000b1; 568 steps/day, respectively, p &#x0003c;0.01). This was associated with reduced energy expenditure and increased sedentary time (p &#x0003c;0.01). Baseline QoL was not different among LVAD, HT, and HF groups (p&#x000a0;= 0.44). LVAD implantation and HT significantly increased daily physical activity by 60% and 52%, respectively, from baseline to 3&#x000a0;months (p &#x0003c;0.05), but the level of activity remained unchanged at 3, 6, and 12&#x000a0;months. The QoL improved from baseline to 3&#x000a0;months in LVAD implantation and HT groups (p&#x000a0;&#x0003c;0.01) but remained unchanged afterward. At any time point, HT demonstrated higher activity level than LVAD implantation (p &#x0003c;0.05), and this was associated with better QoL. In contrast, physical activity and QoL decreased at 12&#x000a0;months in patients with HF (p&#x000a0;&#x0003c;0.05). In conclusion, patients in LVAD and HT patients demonstrate improved physical activity and QoL within the first 3&#x000a0;months after surgery, but physical activity and QoL remain unchanged afterward and well below that of healthy subjects. Strategies targeting low levels of physical activity should now be explored to improve recovery of these patients.</p></abstract></article-meta></front><body><p>Physical inactivity increases the risk for all-cause and cardiovascular mortality by 30% to 40% in the general population<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> and is considered as an independent risk factor for heart failure (HF).<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Conversely, habitual physical activity, that is, daily walking performance, as objectively evaluated by an accelerometer, is an important determinant of functional capacity in patients with chronic HF.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Furthermore, increased physical activity in the form of a structured exercise intervention improves exercise tolerance and quality of life (QoL) in HF<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> and heart transplantation (HT) patients,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> but limited number of studies evaluated its impact in patients implanted with a left ventricular assist device (LVAD).<xref rid="bib6 bib7" ref-type="bibr"><sup>6,7</sup></xref> Before critically evaluating exercise as a potential therapy for patients on LVAD support, it is important to understand the pattern of habitual, daily physical activity and its relation to QoL. Consequently, the aim of this study was to define the short- and long-term effects of LVAD implantation and HT on everyday physical activity, energy expenditure, and QoL.</p><sec sec-type="methods" id="sec1"><title>Methods</title><p>A prospective, observational, repeated-measures design was chosen to characterize changes over time that occur in physical activity and QoL in patients on LVAD support and HT patients. The setting for the study was an inpatient HT assessment. Based on the assessment, patients were listed for HT, if judged to be too unwell to wait for a transplant, or an LVAD was implanted, if they would become better transplant candidates after a period of LVAD support. Those too well for transplant were continued on optimal medical management. These 3 scenarios were the basis of the 3 patients groups: LVAD, HT, and HF. HF patients had not received LVAD or&#x000a0;HT during the study. Changes in physical activity and QoL of 12 HT patients were compared with those of 14 LVAD and 14 HF patients. Physical activity&#x02013;related subgroup comparisons were performed with age-, gender-, and body mass index&#x02013;matched 14 HF patients and 14 healthy subjects. In LVAD and HT patients, data on physical activity and QoL were collected at 4 different time points: baseline assessment, that is, 4 to 6&#x000a0;weeks after surgery and after discharge from hospital and then follow-up assessments at 3, 6, and 12&#x000a0;months after surgery. The data on patients with HF were collected at baseline and at 12&#x000a0;months, and on the healthy subjects data were only collected at 1 time point. Both LVAD and HT patients completed in-hospital postsurgery mobility and rehabilitation program guided by a physiotherapist. The study protocol was approved by the County Durham and Tees Valley Research and Ethics Committee. All participants gave written informed consent. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.</p><p>All patients undergoing LVAD implantation (HeartWare, HeartWare International Inc., Framingham, Massachusetts) or HT who met study inclusion criteria were recruited into the study from September 2010 to June 2013 at the Freeman Hospital, Newcastle upon Tyne, United Kingdom. Their baseline physical activity and QoL data were compared with those of 14&#x000a0;patients with chronic HF who were assessed but not listed for HT and 14 healthy participants. Subjects' demographic and&#x000a0;clinical characteristics are presented in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. The study&#x000a0;inclusion criteria included age from 18 to 60&#x000a0;years, sufficient English language skills to answer the questionnaires, completion of follow-up visits, and willingness to participate. Study exclusion criteria included physical condition limiting rehabilitation or mobility such as stroke; myopathy; neuropathy; renal, pulmonary, or hepatic dysfunction; or active uncontrolled infection. Written informed consent was received from all subjects enrolled in the study.</p><p>Patients on LVAD support were treated with warfarin for a target international normalized ratio of 2.7 and antiplatelets as&#x000a0;well as with angiotensin-converting enzyme inhibitors, &#x003b2;&#x000a0;blockers, aldosterone antagonists, angiotensin receptor blockers, and diuretics as appropriate. HT patients received triple-drug immunosuppressive maintenance therapy, usually including a calcineurin inhibitor, prednisolone, and azathioprine. Patients with chronic HF were treated with &#x003b2; blockers (n&#x000a0;= 14), angiotensin-converting enzyme inhibitors (n&#x000a0;= 10), aldosterone antagonists (n&#x000a0;= 6), diuretics (n&#x000a0;= 12), statins (n&#x000a0;= 8), angiotensin receptor blockers (n&#x000a0;= 5), anticoagulants (n&#x000a0;= 9), antiarrhythmics (n&#x000a0;= 5), and digoxin (n&#x000a0;= 3).</p><p>Habitual physical activity was objectively evaluated using a validated portable multisensor array (SenseWear Pro3, BodyMedia Inc., Pennsylvania).<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> The monitor was worn for 7 days and was only removed for bathing. The multisensor array measures 4 key metrics: skin temperature, galvanic skin response, heat flux, and motion by way of a 3-axis accelerometer. The sensors, combined with algorithms, calculate the average daily energy expenditure relative to baseline metabolism (metabolic equivalent: MET per day [1 MET&#x000a0;= resting metabolic rate]), total energy expenditure (calories per day), active energy expenditure (total calories expended over 3 METs per day), physical activity duration (minutes &#x0003e;3 METs per day), average daily number of steps walked, sedentary activity (minutes &#x0003c;3 METs per day), moderate activity (minutes between 3 and 6 METs per day), vigorous activity (minutes between 6 and 9 METs day), and very vigorous activity (minutes &#x0003e;6 METs day).<xref rid="bib8 bib9" ref-type="bibr"><sup>8,9</sup></xref> HF-related QoL was assessed with the Minnesota Living with Heart Failure (MLHF) Questionnaire.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref></p><p>All statistical analyses were carried out using SPSS, version 19.0 (SPSS Inc., Chicago, Illinois). Before statistical analysis, data were checked for univariate and multivariate outliers using standard z-distribution cutoffs and Mahalanobis distance tests. Normality of distribution was assessed using a Kolmogorov-Smirnov test. Analysis of variance was used to test differences in physical activity and QoL among LVAD, HT, and HF patients and healthy controls as well as to evaluate changes at different time points in LVAD and HT patients. To identify groups that differed significantly from one another, a post hoc Tukey test was performed. The relation between QoL and physical activity in the patients was evaluated using the Pearson coefficient of correlation. Statistical significance was indicated if p &#x0003c;0.05. All data are presented as mean &#x000b1; SEM unless otherwise indicated.</p></sec><sec sec-type="results" id="sec2"><title>Results</title><p>The total number of patients screened for the study was 52&#x000a0;(18 LVAD, 14 HT, and 20 HF). Study participants' demographic and clinical characteristics are described in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. The groups were not randomly assigned, and the treatment was based on the outcome of the transplant assessment. No significant differences were found in age and body mass index among LVAD, HT, HF, and healthy subjects. During the follow-up study, 2 patients in the LVAD group died and 2 refused to complete the study. There were 8 hospitalizations in 7 patients in the LVAD group for infections, 2 hospitalizations for arrhythmias, 1 with HF, 1 anemia, 1 with a transient ischemic attack, 1 with a possible deep vein thrombosis, and 1 with light-headedness. Of the heart transplant patients, 3 patients had admissions for infections and 1 patient had 3 admissions for rejection. Of the 20 patients with HF who were initially screened, 4 refused to take part in the study, 2 received HT, and 10 of remaining 14 patients completed investigation at 12 months after the baseline assessment.</p><p>Baseline physical activity measures demonstrated that patients in the LVAD and HT groups expended 25% (716&#x000a0;kcal) and 22% (640&#x000a0;kcal) less energy per day, respectively, in comparison with healthy subjects (p &#x0003c;0.05). Similarly, patients with HF expended 27% (772&#x000a0;kcal) less energy per day than healthy subjects (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Daily physical activity (i.e., number of steps) was significantly reduced in the 3 patient groups with LVAD and HT patients at baseline performing only 15% and 28% and HF 51% of that of healthy subjects (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). At baseline, duration of physical activity (i.e., &#x0003e;3 METs) was significantly reduced in LVAD patients compared with both HT and HF patients (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). LVAD and HT patients showed active energy expenditure that was significantly lower than that of healthy subjects (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Moderate physical activity, that is, 3 to 6 METs, was a major contributor to active energy expenditure in all 4 groups. Vigorous physical activity was identified in healthy and HT participants but not in LVAD and HF patients (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). The MLHF QoL score was not significantly different among the 3&#x000a0;groups of patients at baseline (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>).</p><p>During the follow-up period there were no significant changes in body mass during 12&#x000a0;months after LVAD implantation or HT. The body mass was also not changed in patients with HF. Total daily energy expenditure increased significantly from baseline to 3&#x000a0;months in LVAD patients (p&#x000a0;&#x0003c;0.05) but remained unchanged from 3 to 12&#x000a0;months after the surgery. In contrast, HT patients demonstrated significantly higher total energy expenditure at 12&#x000a0;months (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>). Daily number of steps significantly increased by 60% and 52% from baseline to 3&#x000a0;months in LVAD and HT patients, respectively. It remained, however, unchanged from 3 to 12&#x000a0;months and significantly lower than that of healthy subjects (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>). This was further associated with significant increase in physical activity duration and active energy expenditure (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>). MLHF scores decreased over time from baseline in both LVAD and HT patients indicating an improvement in QoL (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>, <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>). In contrast with LVAD and HT patients, those with HF had decreased daily number of steps, activity duration, and active energy expenditure at 12&#x000a0;months from baseline and increased MLHF scores (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>).</p><p>At any time point during the 12-month follow-up, LVAD patients demonstrated significantly lower number of steps, physical activity duration, and active energy expenditure in comparison with HT patients (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>). HT patients at 12&#x000a0;months after surgery demonstrated average daily physical activity duration that was only 7% below healthy controls (119 vs 128&#x000a0;min/day) and reached 80% active energy of controls (602 vs 751&#x000a0;kcal/day). The QoL score was significantly lower in HT than in LVAD patients at 3, 6, and 12&#x000a0;months after surgery (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>).</p></sec><sec sec-type="discussion" id="sec3"><title>Discussion</title><p>To our knowledge, this is the first study to report physical activity in patients after LVAD implantation and HT. There are 3 major findings. First, within the first 4 to 6&#x000a0;weeks after surgery, LVAD and HT patients demonstrated low physical activity levels accompanied with low energy expenditure and increased sedentary time. Second, from baseline to 3&#x000a0;months there was a significant increase in physical activity&#x02013;associated measures and improvement in QoL in both LVAD and HT, but the number of steps remained unchanged from 3 to 12&#x000a0;months after surgery. Finally, HT patients demonstrate higher activity level and better QoL than LVAD patients during the 12-month follow-up. In contrast with HT and LVAD patients, those with HF demonstrated a decrease in physical activity&#x02013;associated measures at 12&#x000a0;months compared with baseline.</p><p>The HT and particularly LVAD patients showed low activity levels on hospital discharge. Although both LVAD and HT patients completed in-hospital postsurgery mobility and rehabilitation program, they remained inactive. Strong association between daily walking performance and functional capacity in HF has been reported.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> It is therefore not surprising that LVAD and HT patients a few weeks after surgery demonstrate only &#x0223c;40% and &#x0223c;50% of maximal predicted functional capacity, respectively.<xref rid="bib11 bib12" ref-type="bibr"><sup>11,12</sup></xref> Inactivity, low energy expenditure, and diminished functional performance early after the surgery are likely to be due to a high incidence of psychological distress and deconditioning found in LVAD and HT patients early after the surgery.<xref rid="bib11 bib13" ref-type="bibr"><sup>11,13</sup></xref></p><p>In comparison with baseline, there was a significant improvement in physical activity&#x02013;associated measures and QoL at 3&#x000a0;months after surgery in both LVAD and HT patients. That QoL and functional capacity improve on hospital discharge during longitudinal follow-up of LVAD and HT patients has been previously reported.<xref rid="bib12 bib14 bib15" ref-type="bibr"><sup>12,14,15</sup></xref> It is, however, noticeable that increased daily activity level at 3&#x000a0;months in LVAD and HT patients, found in the present study, is markedly below healthy controls and in case of HT patients similar to that of HF patients. It should further be noted that QoL improved from baseline to 3&#x000a0;months by 24 and 33 points for LVAD and HT patients, respectively. This is important, as a 5-point change in the MLHF score has been previously determined to be clinically meaningful.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Further comparison between the different patient groups reveals that 3&#x000a0;months after surgery, LVAD and HT patients show better QoL than patients with HF. QoL was not changed from 3 to 12&#x000a0;months in LVAD patients, likely because of frequent hospitalization. Our findings further suggest that patients' body mass remained unchanged over time. This is particularly interesting for LVAD patients and contrasts findings from a recent large retrospective study that suggests a significant increase in body mass after a continuous LVAD implantation.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> The limited number of patients recruited in the present study may limit generalization of our findings.</p><p>Our data further suggest that daily number of steps and QoL remained unchanged at 3, 6, and 12&#x000a0;months after surgery for LVAD, but the QoL was further improved at 6&#x000a0;months in HT patients. This is surprising, as a significant improvement in functional capacity has been reported several months after HT and LVAD implantation allowing patients to independently perform activities of daily living.<xref rid="bib12 bib17 bib18" ref-type="bibr"><sup>12,17,18</sup></xref> In agreement with our findings, previous studies also showed that health-related QoL improved from baseline to 3&#x000a0;months after surgery and remained unchanged during 1-year follow-up.<xref rid="bib14 bib19" ref-type="bibr"><sup>14,19</sup></xref></p><p>Finally, our results suggest that, not only at baseline but also at 3, 6, and 12&#x000a0;months after surgery, HT patients demonstrate higher levels of physical activity and better QoL than LVAD patients. These findings are in line with previous studies suggesting greater functional capacity of HT compared with LVAD patients.<xref rid="bib7 bib11 bib12 bib20" ref-type="bibr"><sup>7,11,12,20</sup></xref> In contrast with LVAD patients who showed a plateauing during the follow-up, HT patients at 12&#x000a0;months demonstrated physical activity duration and active energy expenditure that were 93% and 80% of healthy controls, respectively. This is an interesting finding considering that the number of steps remained unchanged from 3 to 12&#x000a0;months. A plausible explanation for such finding is that from 3 to 6&#x000a0;months the intensity of the activity was mostly &#x0003c;3 METs (characterized as sedentary activity), whereas at 12&#x000a0;months moderate activity (3 to 6 METs) was predominantly detected, resulting in a significant increase in activity duration and active energy expenditure. It has further been suggested that vigorous intensity appears to convey greater cardiovascular and functional benefits than exercise of a moderate intensity.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Considering that HT and LVAD are different treatment methods, the optimal physical activity and exercise interventions to improve outcomes in these patients remain to be determined in large clinical trials. Therefore, general recommendations for exercise therapy in HT and LVAD patients need to be considered with caution and are likely to differentiate in volume and intensity from those of general cardiology patients.</p><p>The present study is not without limitations. First, the lack of presurgical activity monitoring prevents our understanding of individual variation in daily activity level between HT and LVAD implantation candidates. Second, small sample size limits the generalizability of our findings. Finally, the study may be biased by the fact that predominantly male patients were available for this analysis, particularly in LVAD group.</p></sec></body><back><ref-list><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Shiroma</surname><given-names>E.J.</given-names></name><name><surname>Lee</surname><given-names>I.M.</given-names></name></person-group><article-title>Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity</article-title><source>Circulation</source><volume>122</volume><year>2010</year><fpage>743</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">20713909</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Ogden</surname><given-names>L.G.</given-names></name><name><surname>Bazzano</surname><given-names>L.A.</given-names></name><name><surname>Vupputuri</surname><given-names>S.</given-names></name><name><surname>Loria</surname><given-names>C.</given-names></name><name><surname>Whelton</surname><given-names>P.K.</given-names></name></person-group><article-title>Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study</article-title><source>Arch Intern Med</source><volume>161</volume><year>2001</year><fpage>996</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">11295963</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Jehn</surname><given-names>M.</given-names></name><name><surname>Schmidt-Trucks&#x000e4;ss</surname><given-names>A.</given-names></name><name><surname>Schuster</surname><given-names>T.</given-names></name><name><surname>Weis</surname><given-names>M.</given-names></name><name><surname>Hanssen</surname><given-names>H.</given-names></name><name><surname>Halle</surname><given-names>M.</given-names></name><name><surname>Koehler</surname><given-names>F.</given-names></name></person-group><article-title>Daily walking performance as an independent predictor of advanced heart failure: prediction of exercise capacity in chronic heart failure</article-title><source>Am Heart J</source><volume>157</volume><year>2009</year><fpage>292</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">19185636</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Pi&#x000f1;a</surname><given-names>I.L.</given-names></name><name><surname>Apstein</surname><given-names>C.S.</given-names></name><name><surname>Balady</surname><given-names>G.J.</given-names></name><name><surname>Belardinelli</surname><given-names>R.</given-names></name><name><surname>Chaitman</surname><given-names>B.R.</given-names></name><name><surname>Duscha</surname><given-names>B.D.</given-names></name><name><surname>Fletcher</surname><given-names>B.J.</given-names></name><name><surname>Fleg</surname><given-names>J.L.</given-names></name><name><surname>Myers</surname><given-names>J.N.</given-names></name><name><surname>Sullivan</surname><given-names>M.J.</given-names></name></person-group><article-title>Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention</article-title><source>Circulation</source><volume>107</volume><year>2003</year><fpage>1210</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">12615804</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Kobashigawa</surname><given-names>J.A.</given-names></name><name><surname>Leaf</surname><given-names>D.A.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Gleeson</surname><given-names>M.P.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Hamilton</surname><given-names>M.A.</given-names></name><name><surname>Moriguchi</surname><given-names>J.D.</given-names></name><name><surname>Kawata</surname><given-names>N.</given-names></name><name><surname>Einhorn</surname><given-names>K.</given-names></name><name><surname>Herlihy</surname><given-names>E.</given-names></name><name><surname>Laks</surname><given-names>H.</given-names></name></person-group><article-title>A&#x000a0;controlled trial of exercise rehabilitation after heart transplantation</article-title><source>N&#x000a0;Engl J Med</source><volume>340</volume><year>1999</year><fpage>272</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">9920951</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Corr&#x000e0;</surname><given-names>U.</given-names></name><name><surname>Pistono</surname><given-names>M.</given-names></name><name><surname>Mezzani</surname><given-names>A.</given-names></name><name><surname>Gnemmi</surname><given-names>M.</given-names></name><name><surname>Tarro Genta</surname><given-names>F.</given-names></name><name><surname>Caruso</surname><given-names>R.</given-names></name><name><surname>Giannuzzi</surname><given-names>P.</given-names></name></person-group><article-title>Cardiovascular prevention and rehabilitation for patients with ventricular assist device from exercise therapy to long-term therapy. Part I: exercise therapy</article-title><source>Monaldi Arch Chest Dis</source><volume>76</volume><year>2011</year><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">21751735</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>de Jonge</surname><given-names>N.</given-names></name><name><surname>Kirkels</surname><given-names>H.</given-names></name><name><surname>Lahpor</surname><given-names>J.R.</given-names></name><name><surname>Kl&#x000f6;pping</surname><given-names>C.</given-names></name><name><surname>Hulzebos</surname><given-names>E.J.</given-names></name><name><surname>de la Riviere</surname><given-names>A.B.</given-names></name><name><surname>Robles de Medina</surname><given-names>E.O.</given-names></name></person-group><article-title>Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation: an outlook for permanent assisting?</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>37</volume><year>2001</year><fpage>1794</fpage><lpage>1799</lpage><pub-id pub-id-type="pmid">11401113</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>St-Onge</surname><given-names>M.</given-names></name><name><surname>Mignault</surname><given-names>D.</given-names></name><name><surname>Allison</surname><given-names>D.B.</given-names></name><name><surname>Rabasa-Lhoret</surname><given-names>R.</given-names></name></person-group><article-title>Evaluation of a portable device to measure daily energy expenditure in free-living adults</article-title><source>Am J Clin Nutr</source><volume>85</volume><year>2007</year><fpage>742</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">17344495</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Jakicic</surname><given-names>J.M.</given-names></name><name><surname>Marcus</surname><given-names>M.</given-names></name><name><surname>Gallagher</surname><given-names>K.I.</given-names></name><name><surname>Randall</surname><given-names>C.</given-names></name><name><surname>Thomas</surname><given-names>E.</given-names></name><name><surname>Goss</surname><given-names>F.L.</given-names></name><name><surname>Robertson</surname><given-names>R.J.</given-names></name></person-group><article-title>Evaluation of the SenseWear Pro Armband to assess energy expenditure during exercise</article-title><source>Med Sci Sports Exerc</source><volume>36</volume><year>2004</year><fpage>897</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">15126727</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Rector</surname><given-names>T.S.</given-names></name><name><surname>Kubo</surname><given-names>S.H.</given-names></name><name><surname>Cohn</surname><given-names>J.N.</given-names></name></person-group><article-title>Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo</article-title><source>Am J Cardiol</source><volume>71</volume><year>1993</year><fpage>1106</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">8475878</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Jaski</surname><given-names>B.E.</given-names></name><name><surname>Lingle</surname><given-names>R.J.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Branch</surname><given-names>K.R.</given-names></name><name><surname>Goldsmith</surname><given-names>R.</given-names></name><name><surname>Johnson</surname><given-names>M.R.</given-names></name><name><surname>Lahpor</surname><given-names>J.R.</given-names></name><name><surname>Icenogle</surname><given-names>T.B.</given-names></name><name><surname>Pi&#x000f1;a</surname><given-names>I.</given-names></name><name><surname>Adamson</surname><given-names>R.</given-names></name><name><surname>Favrot</surname><given-names>L.K.</given-names></name><name><surname>Dembitsky</surname><given-names>W.P.</given-names></name></person-group><article-title>Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial</article-title><source>J&#x000a0;Heart Lung Transpl</source><volume>18</volume><year>1999</year><fpage>1031</fpage><lpage>1140</lpage></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Kugler</surname><given-names>C.</given-names></name><name><surname>Malehsa</surname><given-names>D.</given-names></name><name><surname>Tegtbur</surname><given-names>U.</given-names></name><name><surname>Guetzlaff</surname><given-names>E.</given-names></name><name><surname>Meyer</surname><given-names>A.L.</given-names></name><name><surname>Bara</surname><given-names>C.</given-names></name><name><surname>Haverich</surname><given-names>A.</given-names></name><name><surname>Strueber</surname><given-names>M.</given-names></name></person-group><article-title>Health-related quality of life and exercise tolerance in recipients of heart transplants and left ventricular assist devices: a prospective, comparative study</article-title><source>J&#x000a0;Heart Lung Transpl</source><volume>30</volume><year>2011</year><fpage>204</fpage><lpage>210</lpage></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Heilmann</surname><given-names>C.</given-names></name><name><surname>Kuijpers</surname><given-names>N.</given-names></name><name><surname>Beyersdorf</surname><given-names>F.</given-names></name><name><surname>Berchtold-Herz</surname><given-names>M.</given-names></name><name><surname>Trummer</surname><given-names>G.</given-names></name><name><surname>Stroh</surname><given-names>A.L.</given-names></name><name><surname>Schlensak</surname><given-names>C.</given-names></name><name><surname>Fritzsche</surname><given-names>K.</given-names></name></person-group><article-title>Supportive psychotherapy for patients with heart transplantation or ventricular assist devices</article-title><source>Eur J Cardiothorac Surg</source><volume>39</volume><year>2011</year><fpage>e44</fpage><lpage>e50</lpage><pub-id pub-id-type="pmid">21256042</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>J.G.</given-names></name><name><surname>Aaronson</surname><given-names>K.D.</given-names></name><name><surname>Boyle</surname><given-names>A.J.</given-names></name><name><surname>Russell</surname><given-names>S.D.</given-names></name><name><surname>Milano</surname><given-names>C.A.</given-names></name><name><surname>Pagani</surname><given-names>F.D.</given-names></name><name><surname>Edwards</surname><given-names>B.S.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>John</surname><given-names>R.</given-names></name><name><surname>Conte</surname><given-names>J.V.</given-names></name><name><surname>Farrar</surname><given-names>D.J.</given-names></name><name><surname>Slaughter</surname><given-names>M.S.</given-names></name></person-group><article-title>Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>55</volume><year>2010</year><fpage>1826</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">20413033</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Grady</surname><given-names>K.L.</given-names></name><name><surname>Meyer</surname><given-names>P.M.</given-names></name><name><surname>Dressler</surname><given-names>D.</given-names></name><name><surname>Mattea</surname><given-names>A.</given-names></name><name><surname>Chillcott</surname><given-names>S.</given-names></name><name><surname>Loo</surname><given-names>A.</given-names></name><name><surname>White-Williams</surname><given-names>C.</given-names></name><name><surname>Todd</surname><given-names>B.</given-names></name><name><surname>Ormaza</surname><given-names>S.</given-names></name><name><surname>Kaan</surname><given-names>A.</given-names></name><name><surname>Costanzo</surname><given-names>M.R.</given-names></name><name><surname>Piccione</surname><given-names>W.</given-names></name></person-group><article-title>Longitudinal change in quality of life and impact on survival after left&#x000a0;ventricular assist device implantation</article-title><source>Ann Thorac Surg</source><volume>77</volume><year>2004</year><fpage>1321</fpage><lpage>1327</lpage><pub-id pub-id-type="pmid">15063260</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Emani</surname><given-names>S.</given-names></name><name><surname>Brewer</surname><given-names>R.J.</given-names></name><name><surname>John</surname><given-names>R.</given-names></name><name><surname>Slaughter</surname><given-names>M.S.</given-names></name><name><surname>Lanfear</surname><given-names>D.E.</given-names></name><name><surname>Ravi</surname><given-names>Y.</given-names></name><name><surname>Sundareswaran</surname><given-names>K.S.</given-names></name><name><surname>Farrar</surname><given-names>D.J.</given-names></name><name><surname>Sai-Sudhakar</surname><given-names>C.B.</given-names></name></person-group><article-title>Patients with low compared with high body mass index gain more weight after implantation of a continuous-flow left ventricular assist device</article-title><source>J&#x000a0;Heart Lung Transpl</source><volume>32</volume><year>2013</year><fpage>31</fpage><lpage>35</lpage></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>McDiarmid</surname><given-names>A.</given-names></name><name><surname>Gordon</surname><given-names>B.</given-names></name><name><surname>Wrightson</surname><given-names>N.</given-names></name><name><surname>Robinson-Smith</surname><given-names>N.</given-names></name><name><surname>Pillay</surname><given-names>T.</given-names></name><name><surname>Parry</surname><given-names>G.</given-names></name><name><surname>Schueler</surname><given-names>S.</given-names></name><name><surname>MacGowan</surname><given-names>G.A.</given-names></name></person-group><article-title>Hemodynamic, echocardiographic, and exercise-related effects of the HeartWare left ventricular assist device in advanced heart failure</article-title><source>Congest Heart Fail</source><volume>19</volume><year>2013</year><fpage>11</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22804927</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Jakovljevic</surname><given-names>D.G.</given-names></name><name><surname>George</surname><given-names>R.S.</given-names></name><name><surname>Nunan</surname><given-names>D.</given-names></name><name><surname>Donovan</surname><given-names>G.</given-names></name><name><surname>Bougard</surname><given-names>R.S.</given-names></name><name><surname>Yacoub</surname><given-names>M.H.</given-names></name><name><surname>Birks</surname><given-names>E.J.</given-names></name><name><surname>Brodie</surname><given-names>D.A.</given-names></name></person-group><article-title>The impact of acute reduction of continuous-flow left ventricular assist device support on cardiac and exercise performance</article-title><source>Heart</source><volume>96</volume><year>2010</year><fpage>1390</fpage><lpage>1395</lpage><pub-id pub-id-type="pmid">20643664</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>J.L.</given-names></name><name><surname>Fermin</surname><given-names>D.R.</given-names></name><name><surname>Birks</surname><given-names>E.J.</given-names></name><name><surname>Barton</surname><given-names>P.J.</given-names></name><name><surname>Slaughter</surname><given-names>M.</given-names></name><name><surname>Eckman</surname><given-names>P.</given-names></name><name><surname>Baba</surname><given-names>H.A.</given-names></name><name><surname>Wohlschlaeger</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>L.W.</given-names></name></person-group><article-title>Clinical, molecular, and genomic changes in response to a left ventricular assist device</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>57</volume><year>2011</year><fpage>641</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">21292124</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Pruijsten</surname><given-names>R.V.</given-names></name><name><surname>de Jonge</surname><given-names>N.</given-names></name><name><surname>Kirkels</surname><given-names>J.H.</given-names></name><name><surname>Kl&#x000f6;pping</surname><given-names>C.</given-names></name><name><surname>Doevendans</surname><given-names>P.A.</given-names></name><name><surname>Oosterom</surname><given-names>A.</given-names></name><name><surname>Kemperman</surname><given-names>H.</given-names></name><name><surname>Lahpor</surname><given-names>J.R.</given-names></name></person-group><article-title>Left ventricular assist device: a functional comparison with heart transplantation</article-title><source>Neth Heart J</source><volume>16</volume><year>2008</year><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">18335020</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Swain</surname><given-names>D.P.</given-names></name><name><surname>Franklin</surname><given-names>B.A.</given-names></name></person-group><article-title>Comparison of cardioprotective benefits of vigorous versus moderate intensity aerobic exercise</article-title><source>Am J Cardiol</source><volume>97</volume><year>2006</year><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">16377300</pub-id></element-citation></ref></ref-list><sec id="appsec1"><title>Disclosures</title><p>Dr Jakovljevic is supported by the <funding-source id="gs2">UKRC Centre for Ageing and Activity</funding-source>, Newcastle, United Kingdom. Prof Trenell is supported by the <funding-source id="gs3">NIHR Senior Research Fellowship</funding-source>, London, United Kingdom. Dr MacGowan is supported by the <funding-source id="gs4">British Heart Foundation Clinical Leave Research Fellowship</funding-source> number FS/11/89/29162. The other authors have no conflicts of interest to disclose.</p></sec><ack id="ack0010"><title>Acknowledgment</title><p>The authors thank the participants for contributing to this study. In addition, we acknowledge the significant contribution from Judith Coulson, BSc, the research nurse, for helping with study recruitment, data collection, and follow-up of patients.</p></ack><fn-group><fn id="d32e963"><label>&#x02606;</label><p>This is an open access article under the CC BY-NC-ND license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/" id="ccintref0005">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>).</p></fn><fn id="d32e971"><p>This study was supported by a research grant from the United Kingdom <funding-source id="gs1">National Institute for Health Research Newcastle Biomedical Research Center in Ageing and Chronic Diseases in Newcastle</funding-source>.</p></fn><fn id="d32e977"><p>See page 92 for disclosure information.</p></fn></fn-group></back><floats-group><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Longitudinal changes in the daily number of steps <italic>(A)</italic>, physical activity duration <italic>(B)</italic>, active energy expenditure <italic>(C)</italic>, and QoL <italic>(D)</italic>. Healthy data is a single reference data point and not a longitudinal series of data. <sup>&#x02217;</sup>p &#x0003c;0.05, HT versus LVAD; <sup>&#x02020;</sup>p &#x0003c;0.05, HF versus LVAD; <sup>&#x02021;</sup>p &#x0003c;0.05, HF versus HT.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap id="tbl1" position="float"><label>Table&#x000a0;1</label><caption><p>Subject demographic and clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patients Characteristics</th><th>LVAD<break/>(n&#x000a0;= 14)</th><th>HT<break/>(n&#x000a0;= 12)</th><th>HF<break/>(n&#x000a0;= 14)</th><th>Healthy<break/>Subjects (n&#x000a0;= 14)</th><th>ANOVA<break/>p Value</th></tr></thead><tbody><tr><td>Age (years)</td><td align="char">49&#x000a0;&#x000b1;&#x000a0;14</td><td align="char">48&#x000a0;&#x000b1;&#x000a0;17</td><td align="char">46&#x000a0;&#x000b1;&#x000a0;10</td><td align="char">48&#x000a0;&#x000b1;&#x000a0;14</td><td align="char">0.959</td></tr><tr><td>Men (%)</td><td>100</td><td>70</td><td>67</td><td>71</td><td>&#x02014;</td></tr><tr><td>Weight (kg)</td><td align="char">85&#x000a0;&#x000b1;&#x000a0;16</td><td align="char">77&#x000a0;&#x000b1;&#x000a0;11</td><td align="char">80&#x000a0;&#x000b1;&#x000a0;15</td><td align="char">84&#x000a0;&#x000b1;&#x000a0;17</td><td align="char">0.617</td></tr><tr><td>Height (cm)</td><td align="char">177&#x000a0;&#x000b1;&#x000a0;10</td><td align="char">170&#x000a0;&#x000b1;&#x000a0;8</td><td align="char">169&#x000a0;&#x000b1;&#x000a0;9</td><td align="char">174&#x000a0;&#x000b1;&#x000a0;13</td><td align="char">0.081</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td align="char">27&#x000a0;&#x000b1;&#x000a0;6</td><td align="char">27&#x000a0;&#x000b1;&#x000a0;6</td><td align="char">29&#x000a0;&#x000b1;&#x000a0;5</td><td align="char">27&#x000a0;&#x000b1;&#x000a0;4</td><td align="char">0.725</td></tr><tr><td>Etiology of heart failure</td><td/><td/><td/><td/><td/></tr><tr><td>Idiopathic dilated cardiomyopathy</td><td>5</td><td>6</td><td>11</td><td>N/A</td><td>&#x02014;</td></tr><tr><td>Ischemic cardiomyopathy</td><td>9</td><td>2</td><td>3</td><td>N/A</td><td>&#x02014;</td></tr><tr><td>Other</td><td>&#x02014;</td><td>4</td><td>&#x02014;</td><td>N/A</td><td>&#x02014;</td></tr><tr><td>LVEF (%)</td><td align="char">13&#x000a0;&#x000b1;&#x000a0;2</td><td align="char">14&#x000a0;&#x000b1;&#x000a0;6</td><td align="char">18&#x000a0;&#x000b1;&#x000a0;3</td><td align="char">64&#x000a0;&#x000b1;&#x000a0;8</td><td align="char">0.004<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></td></tr><tr><td>NYHA class</td><td align="char">3.7&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">3.8&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">3.3&#x000a0;&#x000b1;&#x000a0;0.5</td><td>&#x02014;</td><td/></tr><tr><td>Cardiac index (l/min/m<sup>2</sup>)</td><td align="char">1.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">1.8&#x000a0;&#x000b1;&#x000a0;0.3 4</td><td align="char">2.1&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">3.6&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char">0.002<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></td></tr><tr><td>Peak O<sub>2</sub> consumption (ml/kg/min)</td><td align="char">9.9&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="char">10.2&#x000a0;&#x000b1;&#x000a0;2.3</td><td align="char">14.6&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="char">34.6&#x000a0;&#x000b1;&#x000a0;9.2</td><td/></tr><tr><td>INTERMACS score</td><td align="char">2.8&#x000a0;&#x000b1;&#x000a0;0.9</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td><td>&#x02014;</td></tr></tbody></table><table-wrap-foot><fn><p>Other includes tricuspid atresia (&#x000d7;2) and restrictive cardiomyopathy (&#x000d7;2).</p><p>ANOVA&#x000a0;= analysis of variance; HF&#x000a0;= heart failure; HT&#x000a0;= heart transplantation; LVAD&#x000a0;= left ventricular assist device; LVEF&#x000a0;= left ventricular ejection fraction; NYHA&#x000a0;= New York Heart Association functional class.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnlowast"><label>&#x02217;</label><p>Healthy versus LVAD, HT, and chronic heart failure (p &#x0003c;0.01).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table&#x000a0;2</label><caption><p>Energy expenditure, physical activity and quality of life at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>LVAD</th><th>HT</th><th>HF</th><th>Healthy<break/>Subjects</th><th>ANOVA<break/>p Value</th></tr></thead><tbody><tr><td>Total energy expenditure (kcal/day)</td><td align="char">2164&#x000a0;&#x000b1;&#x000a0;112</td><td align="char">2240&#x000a0;&#x000b1;&#x000a0;163</td><td align="char">2108&#x000a0;&#x000b1;&#x000a0;211</td><td align="char">2880&#x000a0;&#x000b1;&#x000a0;153</td><td align="char">0.004<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref></td></tr><tr><td>Steps (per day)</td><td align="char">1603&#x000a0;&#x000b1;&#x000a0;302</td><td align="char">3036&#x000a0;&#x000b1;&#x000a0;439</td><td align="char">5490&#x000a0;&#x000b1;&#x000a0;1058</td><td align="char">10,756&#x000a0;&#x000b1;&#x000a0;568</td><td align="char">&#x0003c;0.001<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl2fndagger" ref-type="table-fn">&#x02020;</xref></td></tr><tr><td>Average METs (kcal/kg/hour)</td><td align="char">1.07&#x000a0;&#x000b1;&#x000a0;0.06</td><td align="char">1.28&#x000a0;&#x000b1;&#x000a0;0.08</td><td align="char">1.23&#x000a0;&#x000b1;&#x000a0;0.06</td><td align="char">1.45&#x000a0;&#x000b1;&#x000a0;0.04</td><td align="char">&#x0003c;0.001<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl2fnddagger" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td>Active energy expenditure (kcal/day)</td><td align="char">78&#x000a0;&#x000b1;&#x000a0;30</td><td align="char">330&#x000a0;&#x000b1;&#x000a0;129</td><td align="char">313&#x000a0;&#x000b1;&#x000a0;95</td><td align="char">751&#x000a0;&#x000b1;&#x000a0;77</td><td align="char">&#x0003c;0.001<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl2fnddagger" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td>Physical activity duration (min/day)</td><td align="char">18&#x000a0;&#x000b1;&#x000a0;8</td><td align="char">69&#x000a0;&#x000b1;&#x000a0;22</td><td align="char">65&#x000a0;&#x000b1;&#x000a0;18</td><td align="char">128&#x000a0;&#x000b1;&#x000a0;10</td><td align="char">&#x0003c;0.001<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl2fnddagger" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td>Sedentary time (min/day)</td><td align="char">1410&#x000a0;&#x000b1;&#x000a0;10</td><td align="char">1303&#x000a0;&#x000b1;&#x000a0;32</td><td align="char">1322&#x000a0;&#x000b1;&#x000a0;24</td><td align="char">1261&#x000a0;&#x000b1;&#x000a0;17</td><td align="char">&#x0003c;0.001<xref rid="tbl2fnddagger" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td>Moderate physical activity (min/day)</td><td align="char">18&#x000a0;&#x000b1;&#x000a0;8</td><td align="char">66&#x000a0;&#x000b1;&#x000a0;25</td><td align="char">64&#x000a0;&#x000b1;&#x000a0;18</td><td align="char">120&#x000a0;&#x000b1;&#x000a0;9</td><td align="char">&#x0003c;0.001<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl2fnddagger" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td>Vigorous physical activity (min/day)</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">3.5&#x000a0;&#x000b1;&#x000a0;2.3</td><td align="char">0.5&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">5.9&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="char">0.014<xref rid="tbl2fnsection" ref-type="table-fn">&#x000a7;</xref></td></tr><tr><td>Very vigorous physical activity (min/day)</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">0.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">1.6&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="char">0.489</td></tr><tr><td>MLHF quality of life</td><td align="char">81&#x000a0;&#x000b1;&#x000a0;5</td><td align="char">72&#x000a0;&#x000b1;&#x000a0;8</td><td align="char">74&#x000a0;&#x000b1;&#x000a0;4</td><td>N/A</td><td align="char">0.445</td></tr></tbody></table><table-wrap-foot><fn><p>ANOVA&#x000a0;= analysis of variance; HF&#x000a0;= heart failure; HT&#x000a0;= heart transplantation; LVAD&#x000a0;= left ventricular assist device; METs&#x000a0;= metabolic equivalent units; MLHF&#x000a0;= Minnesota Living with Heart Failure Questionnaire; N/A&#x000a0;= not applicable.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnlowast"><label>&#x02217;</label><p>Healthy versus LVAD, HT, and HF (p &#x0003c;0.05).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fndagger"><label>&#x02020;</label><p>LVAD versus HF (p &#x0003c;0.05).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnddagger"><label>&#x02021;</label><p>LVAD versus HF, HT, and healthy (p &#x0003c;0.05).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnsection"><label>&#x000a7;</label><p>Healthy and HT versus HF and LVAD (p &#x0003c;0.05).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table&#x000a0;3</label><caption><p>Longitudinal changes in energy expenditure, physical activity, and quality of life</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>Patient Group</th><th>Baseline</th><th>3 Months</th><th>6 Months</th><th>12&#x000a0;Months</th></tr></thead><tbody><tr><td rowspan="3">Weight (kg)</td><td>LVAD</td><td align="char">86&#x000a0;&#x000b1;&#x000a0;17</td><td align="char">86&#x000a0;&#x000b1;&#x000a0;16</td><td align="char">89&#x000a0;&#x000b1;&#x000a0;16</td><td align="char">83&#x000a0;&#x000b1;&#x000a0;11</td></tr><tr><td>HT</td><td align="char">76&#x000a0;&#x000b1;&#x000a0;15</td><td align="char">78&#x000a0;&#x000b1;&#x000a0;14</td><td align="char">77&#x000a0;&#x000b1;&#x000a0;15</td><td align="char">80&#x000a0;&#x000b1;&#x000a0;17</td></tr><tr><td>HF</td><td align="char">81&#x000a0;&#x000b1;&#x000a0;17</td><td>&#x02014;</td><td>&#x02014;</td><td align="char">82&#x000a0;&#x000b1;&#x000a0;16</td></tr><tr><td rowspan="3">Steps (per day)</td><td>LVAD</td><td align="char">1603&#x000a0;&#x000b1;&#x000a0;302</td><td align="char">3712&#x000a0;&#x000b1;&#x000a0;807</td><td align="char">4007&#x000a0;&#x000b1;&#x000a0;1084</td><td align="char">3997&#x000a0;&#x000b1;&#x000a0;956<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref></td></tr><tr><td>HT</td><td align="char">3036&#x000a0;&#x000b1;&#x000a0;439</td><td align="char">6265&#x000a0;&#x000b1;&#x000a0;443</td><td align="char">6563&#x000a0;&#x000b1;&#x000a0;824</td><td align="char">6288&#x000a0;&#x000b1;&#x000a0;701<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref></td></tr><tr><td>HF</td><td align="char">5490&#x000a0;&#x000b1;&#x000a0;1058</td><td>&#x02014;</td><td>&#x02014;</td><td align="char">3560&#x000a0;&#x000b1;&#x000a0;885<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl3fndagger" ref-type="table-fn">&#x02020;</xref></td></tr><tr><td rowspan="3">Total energy expenditure (kcal/day)</td><td>LVAD</td><td align="char">2164&#x000a0;&#x000b1;&#x000a0;112</td><td align="char">2392&#x000a0;&#x000b1;&#x000a0;105</td><td align="char">2398&#x000a0;&#x000b1;&#x000a0;108</td><td align="char">2421&#x000a0;&#x000b1;&#x000a0;117<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref></td></tr><tr><td>HT</td><td align="char">2240&#x000a0;&#x000b1;&#x000a0;163</td><td align="char">2406&#x000a0;&#x000b1;&#x000a0;137</td><td align="char">2443&#x000a0;&#x000b1;&#x000a0;148</td><td align="char">3572&#x000a0;&#x000b1;&#x000a0;202<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td>HF</td><td align="char">2108&#x000a0;&#x000b1;&#x000a0;211</td><td>&#x02014;</td><td>&#x02014;</td><td align="char">1989&#x000a0;&#x000b1;&#x000a0;198<xref rid="tbl3fndagger" ref-type="table-fn">&#x02020;</xref></td></tr><tr><td rowspan="3">Average METs (kcal/kg/hour)</td><td>LVAD</td><td align="char">1.07&#x000a0;&#x000b1;&#x000a0;0.06</td><td align="char">1.18&#x000a0;&#x000b1;&#x000a0;0.07</td><td align="char">1.19&#x000a0;&#x000b1;&#x000a0;0.08</td><td align="char">1.20&#x000a0;&#x000b1;&#x000a0;0.09</td></tr><tr><td>HT</td><td align="char">1.28&#x000a0;&#x000b1;&#x000a0;0.08<xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td><td align="char">1.31&#x000a0;&#x000b1;&#x000a0;0.05</td><td align="char">1.35&#x000a0;&#x000b1;&#x000a0;0.07<xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td><td align="char">1.39&#x000a0;&#x000b1;&#x000a0;0.06<xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td>HF</td><td align="char">1.23&#x000a0;&#x000b1;&#x000a0;0.06</td><td>&#x02014;</td><td>&#x02014;</td><td align="char">1.14&#x000a0;&#x000b1;&#x000a0;0.05<xref rid="tbl3fndagger" ref-type="table-fn">&#x02020;</xref></td></tr><tr><td rowspan="3">Sedentary time (min/day)</td><td>LVAD</td><td align="char">1410&#x000a0;&#x000b1;&#x000a0;10</td><td align="char">1353&#x000a0;&#x000b1;&#x000a0;26</td><td align="char">1293&#x000a0;&#x000b1;&#x000a0;52</td><td align="char">1280&#x000a0;&#x000b1;&#x000a0;62</td></tr><tr><td>HT</td><td align="char">1303&#x000a0;&#x000b1;&#x000a0;32</td><td align="char">1308&#x000a0;&#x000b1;&#x000a0;21</td><td align="char">1329&#x000a0;&#x000b1;&#x000a0;18</td><td align="char">1260&#x000a0;&#x000b1;&#x000a0;29</td></tr><tr><td>HF</td><td align="char">1322&#x000a0;&#x000b1;&#x000a0;24</td><td>&#x02014;</td><td>&#x02014;</td><td align="char">1388&#x000a0;&#x000b1;&#x000a0;21<xref rid="tbl3fndagger" ref-type="table-fn">&#x02020;</xref></td></tr><tr><td rowspan="3">Moderate physical activity (min/day)</td><td>LVAD</td><td align="char">18&#x000a0;&#x000b1;&#x000a0;8</td><td align="char">48&#x000a0;&#x000b1;&#x000a0;17</td><td align="char">55&#x000a0;&#x000b1;&#x000a0;16</td><td align="char">51&#x000a0;&#x000b1;&#x000a0;20<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref></td></tr><tr><td>HT</td><td align="char">66&#x000a0;&#x000b1;&#x000a0;22<xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td><td align="char">86&#x000a0;&#x000b1;&#x000a0;46<xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td><td align="char">84&#x000a0;&#x000b1;&#x000a0;14<xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td><td align="char">144&#x000a0;&#x000b1;&#x000a0;22<xref rid="tbl3fnsection" ref-type="table-fn">&#x000a7;</xref><xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td>HF</td><td align="char">64&#x000a0;&#x000b1;&#x000a0;18</td><td>&#x02014;</td><td>&#x02014;</td><td align="char">41&#x000a0;&#x000b1;&#x000a0;12<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl3fndagger" ref-type="table-fn">&#x02020;</xref></td></tr><tr><td rowspan="3">Vigorous physical activity (min/day)</td><td>LVAD</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">1.3&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char">2.4&#x000a0;&#x000b1;&#x000a0;1.9</td><td align="char">0.5&#x000a0;&#x000b1;&#x000a0;0.3</td></tr><tr><td>HT</td><td align="char">3.5&#x000a0;&#x000b1;&#x000a0;2.3</td><td align="char">2.3&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="char">2.9&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="char">4.3&#x000a0;&#x000b1;&#x000a0;2.3</td></tr><tr><td>HF</td><td align="char">0.5&#x000a0;&#x000b1;&#x000a0;0.3</td><td>&#x02014;</td><td>&#x02014;</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td></tr><tr><td rowspan="3">Very vigorous physical activity (min/day)</td><td>LVAD</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td></tr><tr><td>HT</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td></tr><tr><td>HF</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td><td>&#x02014;</td><td>&#x02014;</td><td align="char">0&#x000a0;&#x000b1;&#x000a0;0</td></tr><tr><td rowspan="3">MLHF quality of life</td><td>LVAD</td><td align="char">81&#x000a0;&#x000b1;&#x000a0;5</td><td align="char">57&#x000a0;&#x000b1;&#x000a0;7</td><td align="char">63&#x000a0;&#x000b1;&#x000a0;7</td><td align="char">60&#x000a0;&#x000b1;&#x000a0;5<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref></td></tr><tr><td>HT</td><td align="char">72&#x000a0;&#x000b1;&#x000a0;8</td><td align="char">39&#x000a0;&#x000b1;&#x000a0;5<xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td><td align="char">30&#x000a0;&#x000b1;&#x000a0;6<xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td><td align="char">29&#x000a0;&#x000b1;&#x000a0;7<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl3fnddagger" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td>HF</td><td align="char">74&#x000a0;&#x000b1;&#x000a0;4</td><td>&#x02014;</td><td>&#x02014;</td><td align="char">82&#x000a0;&#x000b1;&#x000a0;6<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref><xref rid="tbl3fndagger" ref-type="table-fn">&#x02020;</xref><xref rid="tbl3fnverbar" ref-type="table-fn">&#x02016;</xref></td></tr></tbody></table><table-wrap-foot><fn id="tbl3fnlowast"><label>&#x02217;</label><p>p &#x0003c;0.05, 12&#x000a0;months versus baseline.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fndagger"><label>&#x02020;</label><p>p &#x0003c;0.05, HF versus HT.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnddagger"><label>&#x02021;</label><p>p &#x0003c;0.05, HT versus LVAD.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnsection"><label>&#x000a7;</label><p>p &#x0003c;0.05, 12&#x000a0;months versus 3 and 6&#x000a0;months.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnverbar"><label>&#x02016;</label><p>p &#x0003c;0.05, HF versus LVAD.</p></fn></table-wrap-foot></table-wrap></floats-group></article>